Publications

2021

Karkampouna S, La Manna F, Benjak A, Kiener M, De Menna M, Zoni E, et al. Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat Commun. 2021;12(1):1117.
Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, et al. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance. 2021;4(2).
Yang HS, Hou Y, Zhang H, Chadburn A, Westblade LF, Fedeli R, et al. Machine Learning Highlights Downtrending of COVID-19 Patients with a Distinct Laboratory Profile. Health Data Sci. 2021;2021:7574903.
Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.
Wang L, Liu D, Yung L, Rodriguez GD, Prasad N, Segal-Maurer S, et al. Co-Infection with 4 Species of Mycobacteria Identified by Using Next-Generation Sequencing. Emerg Infect Dis. 2021;27(11):2948-2950.
Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.
Imada EL, Sanchez DF, Dinalankara W, Vidotto T, Ebot EM, Tyekucheva S, et al. Transcriptional landscape of PTEN loss in primary prostate cancer. BMC Cancer. 2021;21(1):856.
Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.
Stupnikov A, Sizykh A, Budkina A, Favorov A, Afsari B, Wheelan S, et al. Hobotnica: exploring molecular signature quality. F1000Res. 2021;10:1260.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700